EU Sees One in 5,000 Cancer Risk from Tainted China Heart Drug

  1. Home
  2. Rx-360 News
  3. Rx-360 Alerts
  4. EU Sees One in 5,000 Cancer Risk from Tainted China Heart Drug

The European Medicines Agency estimates there could be one extra case of cancer for every 5,000 patients taking a common blood pressure and heart drug manufactured in bulk by a Chinese company that has been found to contain an impurity.

The alarm over valsartan was first raised in July, prompting a global recall of affected pills. The EMA believes the problem likely dates back to changes in manufacturing processes at Zhejiang Huahai Pharmaceutical in 2012.

Click here to view full article.

Menu